Sarepta Therapeutics【SRPT】株式ニュース

名称	銘柄コード	市場	種別
Sarepta Therapeutics Inc New	SRPT	NASDAQ	普通株式

	前日比	前日比 %	現在値	時刻
	5.71	4.59%	130.16	09:00:00

始値	安値	高値	終値	前日終値
125.48	125.40	130.81	129.86	124.45

この銘柄の詳細情報 »

最新ニュース

日付	時間	ソース	タイトル
2024/6/01	06:45	BW	Sarepta Therapeutics Announces Inducement Grants Under..
2024/5/30	06:48	PRNUS	Sarepta Therapeutics Set to Join S&P MidCap 400
2024/5/07	09:09	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
2024/5/07	09:00	EDGAR2	Form 3 - Initial statement of beneficial ownership of..
2024/5/03	23:07	BW	Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to..
2024/5/02	05:05	BW	Sarepta Therapeutics Announces First Quarter 2024 Financial..
2024/5/01	07:38	BW	Sarepta Therapeutics Announces Inducement Grants Under..
2024/4/24	21:30	BW	Sarepta Therapeutics to Announce First Quarter 2024..
2024/3/30	05:00	BW	Sarepta Therapeutics Announces Inducement Grants Under..
2024/3/09	07:38	EDGAR2	Form 144 - Report of proposed sale of securities
2024/3/07	10:00	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
2024/3/07	10:00	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
2024/3/07	10:00	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
2024/3/07	10:00	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
2024/3/07	10:00	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
2024/3/06	10:00	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
2024/3/06	10:00	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
2024/3/06	10:00	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
2024/3/06	10:00	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
2024/3/06	10:00	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
2024/3/06	10:00	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
2024/3/06	10:00	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
2024/3/06	10:00	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
2024/3/06	10:00	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
2024/3/06	07:34	EDGAR2	Form 144 - Report of proposed sale of securities
2024/3/04	22:30	BW	Sarepta Therapeutics to Present at Upcoming Investor..
2024/3/02	09:55	EDGAR2	Form 144 - Report of proposed sale of securities
2024/3/02	09:42	EDGAR2	Form 144 - Report of proposed sale of securities
2024/3/02	06:47	EDGAR2	Form 144 - Report of proposed sale of securities
2024/3/01	08:16	BW	Sarepta Therapeutics Announces Inducement Grants Under..
2024/2/29	23:00	BW	Sarepta Therapeutics Announces Call for Applications for the..
2024/2/29	06:05	BW	Sarepta Therapeutics Announces Fourth Quarter and Full-Year..
2024/2/21	22:30	BW	Sarepta Therapeutics to Announce Fourth Quarter and..
2024/2/16	21:00	BW	Sarepta Therapeutics Announces U.S. FDA Acceptance of an..
2024/2/14	03:34	EDGAR2	Form SC 13G/A - Statement of acquisition of beneficial..
2024/2/10	08:05	EDGAR2	Form SC 13G - Statement of acquisition of beneficial..
2024/2/01	08:29	BW	Sarepta Therapeutics Announces Inducement Grants Under..
2024/1/29	21:00	BW	Sarepta Therapeutics Announces Positive Data from Part B of..
2024/1/16	23:02	BW	Sarepta Therapeutics Initiates Screening in EMERGENE, a..
2024/1/09	02:08	EDGAR2	Form 8-K - Current report
2024/1/09	01:55	BW	Sarepta Therapeutics Reports Preliminary* Fourth Quarter and..
2024/1/02	22:30	BW	Sarepta Therapeutics to Present at the 42nd Annual J.P...
2023/12/30	08:27	BW	Sarepta Therapeutics Announces Inducement Grants Under..
2023/12/22	22:00	BW	Sarepta Therapeutics Submits Efficacy Supplement to Expand..
2023/12/06	10:00	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
2023/12/01	08:34	BW	Sarepta Therapeutics Announces Inducement Grants Under..
2023/11/21	10:00	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
2023/11/06	22:00	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
2023/11/06	22:00	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
2023/11/06	22:00	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..